Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies | Zendy

Andrea De Giglio | Zendy; Giacomo Nuvola | Zendy; Filippo Gustavo Dall’Olio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies

Author(s) -

Andrea De Giglio,

Giacomo Nuvola,

Filippo Gustavo Dall’Olio

Publication year - 2019

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2019.12.69

Subject(s) - atezolizumab , carboplatin , paclitaxel , medicine , oncology , cornerstone , lung cancer , chemotherapy , intensive care medicine , cancer , cisplatin , immunotherapy , pembrolizumab , art , visual arts

In the last decade, the management of advanced non-small cell lung cancer (NSCLC) has radically changed. The standard chemotherapy treatment based on histology constituted for 25 years the cornerstone of anticancer treatment, but was finally put aside when molecular diagnosis and precision medicine have modified the therapeutic algorithm.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research